Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction‐associated steatohepatitis?

Ähnliche Einträge

• Hepatic thyroid hormone receptor‐β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction‐associated steatohepatitis
  von: Stergios A. Polyzos, et al.
  Veröffentlicht: (2024)
• The US Food and Drug administration has approved resmetirom as the first drug to treat metabolic dysfunction‐associated steatohepatitis (MASH)
  von: Iskandar Idris
  Veröffentlicht: (2024)
• The effects of anti‐obesity medications on bone metabolism: A critical appraisal
  von: Athanasios D. Anastasilakis, et al.
  Veröffentlicht: (2025)
• A review of multidisciplinary care in metabolic dysfunction‐associated steatohepatitis and cardiometabolic disease, with a focus on Canada
  von: James Kim, et al.
  Veröffentlicht: (2025)
• Efsubaglutide Alfa attenuates metabolic dysfunction‐associated steatohepatitis in mice with improvements in second harmonic generation‐derived fibrosis features
  von: Yahao Wang, et al.
  Veröffentlicht: (2026)